NCT06679829 2026-02-19
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
3 trialsNCT05316116 2026-02-05
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Terminated
NCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting